Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
IH

WKN: A424KD | ISIN: US45333F2083 | Ticker:
NASDAQ
17.11.26 | 21:53
1,750 US-Dollar
+0,57 % +0,010
Branche
Gesundheitswesen
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
INCANNEX HEALTHCARE INC Chart 1 Jahr
5-Tage-Chart
INCANNEX HEALTHCARE INC 5-Tage-Chart

Aktuelle News zur INCANNEX HEALTHCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoIncannex Healthcare Inc. - 10-Q, Quarterly Report-
01.10.Stonegate, Inc.: Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26887Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26...
► Artikel lesen
25.09.Incannex Healthcare Inc. - 10-K, Annual Report1
INCANNEX HEALTHCARE Aktie jetzt für 0€ handeln
09.09.Incannex begins Phase 2 dosing study for sleep apnea drug2
09.09.Incannex Healthcare Inc. - 8-K, Current Report1
25.08.Incannex Healthcare: Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X263NEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative...
► Artikel lesen
25.08.Incannex Healthcare Inc. - 8-K, Current Report2
11.08.Incannex receives final A$5.1m R&D tax incentive refund2
11.08.Incannex Healthcare Inc. - 8-K, Current Report1
23.07.Incannex Healthcare: Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea339First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast...
► Artikel lesen
23.07.Incannex Healthcare Inc. - 8-K, Current Report1
25.06.Incannex receives U.S. patent for sleep apnea drug IHL-42X2
25.06.Incannex Healthcare: Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea693MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative...
► Artikel lesen
25.06.Incannex Healthcare Inc. - 8-K, Current Report-
10.06.Incannex Healthcare: Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility564NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative...
► Artikel lesen
09.06.Incannex Healthcare: Incannex Announces Initiation of Research Coverage by Alliance Global Partners411MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative...
► Artikel lesen
09.06.Incannex Healthcare Inc. - 8-K, Current Report2
14.05.Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea713MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for...
► Artikel lesen
17.03.Incannex Healthcare: Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement557MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact...
► Artikel lesen
12.03.Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules613NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the "Company") a clinical-stage biopharmaceutical company leading the...
► Artikel lesen
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1